{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:02:27Z","timestamp":1790870547602,"version":"4.1.0"},"reference-count":47,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background and Objectives: Community pharmacies in Poland administer an expanding range of adult vaccines, including influenza, COVID-19, respiratory syncytial virus (RSV), herpes zoster and pneumococcal vaccines. While pharmacist vaccination services are increasingly available, evidence on structured approaches supporting vaccine coadministration remains limited. This study assessed whether a structured pharmacist-led recommendation and coadministration protocol was associated with greater uptake of multiple vaccines and same-day coadministration in routine community pharmacy practice. Methods: This non-randomized real-world study used anonymized vaccination records from three community pharmacies in northern Poland between 1 August 2025 and 31 March 2026. One pharmacy implemented a multicomponent protocol combining proactive identification of eligible patients, presumptive recommendation and same-day coadministration, while two comparator pharmacies operated under routine practice. Outcomes included the mean number of vaccine types per patient, the proportion of patients receiving at least two of five analyzed vaccines, same-day coadministration among multi-vaccine patients, and the RSV-to-(influenza + COVID-19) vaccination ratio. A Poisson regression model with robust standard errors was used to assess relative RSV uptake. As the dataset comprised only patients who received at least one vaccination, these findings describe vaccination patterns among presenting, already-vaccinated patients rather than uptake relative to the total eligible or registered pharmacy population, for which denominators were not available. Results: Overall, 3248 patients contributed 5505 unique patient-vaccine events. The intervention pharmacy achieved a higher mean number of vaccine types per patient than comparator pharmacies (2.08 vs. approximately 1.54). The proportion of patients receiving at least two vaccine types was 73.6% (685\/931) in the intervention pharmacy compared with 42.7% (990\/2317) in comparator pharmacies. Among multi-vaccine patients, same-day coadministration occurred in 92.7% (635\/685) of intervention-site patients versus 73.1% (724\/990) in comparator pharmacies. Triple-vaccine coadministration visits were observed exclusively in the intervention pharmacy. RSV uptake was higher in the intervention pharmacy (incidence rate ratio 2.17; 95% CI 1.67\u20132.84; p &lt; 0.001). An age- and sex-adjusted analysis of multi-vaccine uptake yielded a materially unchanged association (adjusted OR 4.42; 95% CI 3.71\u20135.28) relative to the unadjusted estimate (OR 3.73; 95% CI 3.16\u20134.41). The exploratory temporal-interaction analysis was not statistically significant when all months were included (interaction IRR 0.84; 95% CI 0.69\u20131.02; p = 0.085), whereas a sensitivity analysis excluding March 2026 suggested a narrowing relative RSV-rate advantage over time (interaction IRR 0.79; 95% CI 0.70\u20130.89; p &lt; 0.001). Conclusions: A structured pharmacist-led recommendation and coadministration protocol was associated with substantially greater uptake of multiple vaccines among vaccinated patients, more frequent same-day coadministration and higher RSV uptake compared with routine practice. These findings suggest that workflow organization, proactive patient identification and systematic recommendation strategies may improve the efficiency of adult vaccination delivery in community pharmacies. Larger multicenter studies are warranted to confirm these findings and evaluate individual protocol components.<\/jats:p>","DOI":"10.3390\/vaccines14090823","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:35:28Z","timestamp":1790868928000},"page":"823","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Structured Pharmacist-Led Vaccine Recommendation and Coadministration in Community Pharmacies: Real-World Evidence from Poland"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5328-6387","authenticated-orcid":false,"given":"Ewa","family":"Kuczwalska","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, ul. Banacha 1, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-8307","authenticated-orcid":false,"given":"Anna Maria","family":"Dworakowska","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, ul. Banacha 1, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Skar\u017cy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, ul. Banacha 1, 02-097 Warsaw, Poland"},{"name":"Clinical Trials Department, Center of Hearing and Speech, ul. Mokra 7, 05-830 Kajetany, Poland"},{"name":"Institute of Sensory Organs, ul. Mokra 1, 05-830 Kajetany, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Bujalska-Zadro\u017cny","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Pharmaceutical Care, Faculty of Pharmacy, Medical University of Warsaw, ul. Banacha 1, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cmi.2026.01.002","article-title":"Prevalence and clinical outcomes of respiratory syncytial virus, COVID-19, and influenza among older hospitalized adults: The EVERY prospective cohort study","volume":"32","author":"Morimoto","year":"2026","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101396","DOI":"10.1016\/j.lanepe.2025.101396","article-title":"Excess mortality and hospitalisations associated with respiratory syncytial virus, influenza, and COVID-19 among adults in Denmark (2015\u20132024): A modelling study","volume":"55","author":"Hansen","year":"2025","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s10096-025-05342-y","article-title":"Burden of respiratory syncytial virus (RSV) vs. influenza (A\/B) in adults \u2265 50 years: A Pre-COVID-19 multicenter retrospective study","volume":"45","author":"Davido","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.japh.2016.03.006","article-title":"The impact of pharmacist immunization programs on adult immunization rates: A systematic review and meta-analysis","volume":"56","author":"Baroy","year":"2016","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1016\/j.vaccine.2016.08.085","article-title":"Impact of pharmacists as immunizers on vaccination rates: A systematic review and meta-analysis","volume":"34","author":"Isenor","year":"2016","journal-title":"Vaccine"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.sapharm.2025.06.110","article-title":"Impact of pharmacist-led interventions on COVID-19, herpes zoster, influenza, pneumococcal, and respiratory syncytial virus vaccines uptake in people aged 60 years and older: Systematic review and meta-analysis","volume":"21","author":"Amare","year":"2025","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_7","first-page":"359","article-title":"Community pharmacist\u2013administered influenza immunization improves patient access to vaccination","volume":"147","author":"Papastergiou","year":"2014","journal-title":"Can. Pharm. J. Rev. Pharm. Can."},{"key":"ref_8","unstructured":"Ministry of Health (2026, August 27). Announcement of the Minister of Health of 23 December 2025 on the List of Protective Vaccinations Performed in Pharmacies That May Be Fully or Partly Financed from Public Funds, Available online: https:\/\/dziennikmz.mz.gov.pl\/legalact\/2025\/103."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.sapharm.2020.05.033","article-title":"The legal extension of the role of pharmacists in light of the COVID-19 global pandemic","volume":"17","author":"Merks","year":"2021","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_10","unstructured":"Ministry of Health (2026, September 15). Regulation of the Minister of Health of 27 September 2023 on Mandatory Preventive Vaccinations, Available online: https:\/\/isap.sejm.gov.pl\/isap.nsf\/DocDetails.xsp?id=WDU20250000782."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e70186","DOI":"10.1002\/iid3.70186","article-title":"Disparities in Seasonal Influenza Vaccination in Europe","volume":"13","author":"Palache","year":"2025","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_12","unstructured":"Eurostat (2026, August 27). Vaccination Against Influenza of Population Aged 65 and Over. Eurostat Data Browser 2026. Available online: https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/hlth_ps_immu__custom_18695796\/default\/table."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1080\/21645515.2016.1215393","article-title":"Community pharmacies as sites of adult vaccination: A systematic review","volume":"12","author":"Burson","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Romero-Mancilla, M.S., Mora-Vargas, J., and Ruiz, A. (2023). Pharmacy-based immunization: A systematic review. Front. Public Health, 11.","DOI":"10.3389\/fpubh.2023.1152556"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.clinthera.2017.07.004","article-title":"Impact of Pharmacist Immunization Authority on Seasonal Influenza Immunization Rates Across States","volume":"39","author":"Drozd","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2055422","DOI":"10.1080\/21645515.2022.2055422","article-title":"Vaccine uptake and barriers to vaccination among at-risk adult populations in the US","volume":"18","author":"Kolobova","year":"2022","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Seweryn, M., Augusty\u0144ska, J., Kopel, J., Jaworski, R., W\u00f3jcik, A., Paradowska-Stankiewicz, I., and Czech, M. (2025). Public spending on immunisation in Poland. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1682169"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5114\/fmpcr.2025.154536","article-title":"RSV prevention in adults: Consensus of experts of Polish scientific societies","volume":"27","author":"Antczak","year":"2025","journal-title":"Fam. Med. Prim. Care Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.5114\/fmpcr.2025.146977","article-title":"Recommendations of Polish experts for 2024 on the co-administration of vaccines in adults for the prevention of respiratory infections","volume":"27","author":"Antczak","year":"2025","journal-title":"Fam. Med. Prim. Care Rev."},{"key":"ref_20","unstructured":"Centers for Disease Control and Prevention (2026, September 15). Best Practices for Patient Care: Coadministration of Flu, COVID-19, and RSV Vaccines in Adults for the 2025\u20132026 Respiratory Virus Season, Available online: https:\/\/www.cdc.gov\/respiratory-viruses\/hcp\/clinical-overview\/index.html."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-2600(21)00557-9","article-title":"Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged \u226565 years: A phase 2, randomised, open-label study","volume":"10","author":"Izikson","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4647","DOI":"10.1016\/j.vaccine.2015.05.003","article-title":"Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults","volume":"33","author":"Song","year":"2015","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/S0140-6736(21)02329-1","article-title":"Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): A multicentre, randomised, controlled, phase 4 trial","volume":"398","author":"Lazarus","year":"2021","journal-title":"Lancet"},{"key":"ref_24","unstructured":"Centers for Disease Control and Prevention (2026, August 27). Strategies for Increasing Adult Vaccination Rates, Available online: https:\/\/www.cdc.gov\/vaccines-adults\/hcp\/vaccination-guidelines\/index.html."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/S0140-6736(21)02507-1","article-title":"Promoting COVID-19 vaccine acceptance: Recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA","volume":"398","author":"Omer","year":"2021","journal-title":"Lancet"},{"key":"ref_26","unstructured":"Polish Chamber of Pharmacists (2026, August 27). Position on Charging a Fee for Issuing a Reimbursed Pharmacist Prescription for a Reimbursed Immunological Product Necessary to Perform a Recommended Vaccination in a Pharmacy. Available online: https:\/\/www.nia.org.pl\/wp-content\/uploads\/2025\/02\/Stan.-ws.-braku-podstaw-do-pob.-oplaty-za-wyst.-r.-farm.-refundowanej-.pdf."},{"key":"ref_27","unstructured":"Ministry of Health (Poland) (2026, August 27). Announcement of the Minister of Health of 19 March 2025 on the List of Reimbursed Medicines, Special-Purpose Nutritional Foodstuffs and Medical Devices Effective 1 April 2025, Available online: https:\/\/www.gov.pl\/web\/zdrowie\/obwieszczenie-ministra-zdrowia-z-dnia-19-marca-2025-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-kwietnia-2025-r."},{"key":"ref_28","unstructured":"Polish Institute of Public Health\u2013National Institute of Hygiene (PZH-PIB) (2026, August 27). Which Vaccines Are on the List of Reimbursed Medicines? 2025, Available online: https:\/\/szczepienia.pzh.gov.pl\/faq\/jakie-szczepionki-sa-na-liscie-lekow-refundowanych\/."},{"key":"ref_29","unstructured":"e-Health Centre (CeZ) (2026, August 27). User Manual for the e-Rejestracja System\u2014Vaccination Point Module, Available online: https:\/\/ezdrowie.gov.pl\/portal\/home\/podrecznik-uzytkownika-systemu-e-rejestracji-punkt-szczepien."},{"key":"ref_30","unstructured":"Ministry of Health (2026, August 27). Principles for Correct Reporting of Protective Vaccinations Performed in Pharmacies, Available online: https:\/\/www.gov.pl\/web\/zdrowie\/zasady-dla-aptek-w-zakresie-prawidlowego-raportowania-szczepien-ochronnych."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Vandenbroucke, J.P., von Elm, E., Altman, D.G., G\u00f8tzsche, P.C., Mulrow, C.D., Pocock, S.J., Poole, C., Schlesselman, J.J., Egger, M. (2007). Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. PLoS Med., 4.","DOI":"10.1371\/journal.pmed.0040297"},{"key":"ref_32","unstructured":"World Health Organization (2025). Recommended Composition of Influenza Virus Vaccines for Use in the 2025\u20132026 Northern Hemisphere Influenza Season, World Health Organization. Available online: https:\/\/www.who.int\/publications\/m\/item\/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2025-2026-nh-influenza-season."},{"key":"ref_33","unstructured":"European Medicines Agency (2025). Abrysvo: Procedural Steps Taken and Scientific Information After Authorisation\u2014Extension of Indication to Adults 18 Through 59 Years of Age, European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/abrysvo."},{"key":"ref_34","unstructured":"National Institute of Public Health\u2013NIH\u2013National Research Institute (PZH) (2026, August 27). Extension of Age Indications for the RSV Vaccine, Available online: https:\/\/szczepienia.pzh.gov.pl\/rozszerzenie-wskazan-dotyczacych-wieku-dla-szczepionki-przeciw-rsv\/."},{"key":"ref_35","unstructured":"National Institute of Public Health\u2013NIH\u2013National Research Institute (2026, August 27). The Role of Pharmacists in Adult Vaccination: Expert Position on Recommended Vaccinations and Pharmacy-Based Delivery, Available online: https:\/\/szczepienia.pzh.gov.pl\/rola-farmaceuty-w-szczepieniach-osob-doroslych-stanowisko-ekspertow-w-sprawie-szczepien-zalecanych-w-aptekach\/."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Loskutova, N., Smail, C., Webster, B., Ajayi, K., Wood, J., and Carroll, J. (2017). Missed opportunities for improving practice performance in adult immunizations: A meta-narrative review of the literature. BMC Fam. Pract., 18.","DOI":"10.1186\/s12875-017-0694-1"},{"key":"ref_37","unstructured":"International Pharmaceutical Federation (FIP) (2026, August 27). FIP Global Vaccination Advocacy Toolkit: Supporting and Expanding Immunisation Coverage Through Pharmacists. Available online: https:\/\/www.fip.org\/files\/content\/fip-council-documents\/Council-documents\/FIP-VaccinationToolkit.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1542\/peds.2013-2037","article-title":"The Architecture of Provider-Parent Vaccine Discussions at Health Supervision Visits","volume":"132","author":"Opel","year":"2013","journal-title":"Pediatrics"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kuczwalska, E., Dworakowska, A.M., Skar\u017cy\u0144ska, M., and Bujalska-Zadro\u017cny, M. (2026). Effectiveness of pharmacist-delivered vaccination recommendations for herpes zoster: A systematic review. Front. Public Health, 14.","DOI":"10.3389\/fpubh.2026.1884479"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(24)00589-9","article-title":"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: An observer-blinded, placebo-controlled, randomised, phase 3 trial","volume":"25","author":"Goswami","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"ofae631.172","DOI":"10.1093\/ofid\/ofae631.172","article-title":"Safety and Immunogenicity of Coadministered Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine With and Without Quadrivalent Influenza Vaccine in Adults \u2265 65 Years of Age","volume":"12","author":"Neutel","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Wei, Z., and Yu, S. (2025). Real-world feasibility of co-administration of RSV, COVID-19, and influenza vaccines in older adults: A VAERS-based analysis. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1682119"},{"key":"ref_43","unstructured":"UK Health Security Agency (2026, August 27). Respiratory Syncytial Virus (RSV) Vaccination of Older Adults: Information For Healthcare Practitioners, Available online: https:\/\/www.gov.uk\/government\/publications\/respiratory-syncytial-virus-rsv-programme-information-for-healthcare-professionals\/rsv-vaccination-of-older-adults-information-for-healthcare-practioners."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e70090","DOI":"10.1111\/irv.70090","article-title":"Adult Vaccine Coadministration Is Safe, Effective, and Acceptable: Results of a Survey of the Literature","volume":"19","author":"Tan","year":"2025","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2592425","DOI":"10.1080\/21645515.2025.2592425","article-title":"Safety of co-administration of injectable vaccines in individuals under 18 years of age: A systematic literature review","volume":"21","author":"Boccalini","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2525603","DOI":"10.1080\/21645515.2025.2525603","article-title":"The safety of co-administration of recombinant zoster vaccine (Shingrix) and influenza vaccines in the elderly in VAERS during 2018\u20132024","volume":"21","author":"Li","year":"2025","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_47","unstructured":"Ontario Immunization Advisory Committee Recommendations: Clinical Considerations for the Co-Administration of RSV, COVID-19 and Influenza Vaccines Among Older Adults in Long-Term Care Facilities, Public Health Ontario. Available online: https:\/\/www.publichealthontario.ca\/-\/media\/Documents\/O\/2023\/oiac-clinical-considerations-co-admin-covid-19-influenza-vaccines-ltc.pdf."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/823\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:36:06Z","timestamp":1790868966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090823"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090823","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}